- In patients with newly diagnosed multiple myeloma (MM), maintenance ixazomib after autologous stem cell transplantation (ASCT) delivered a significant improvement in PFS, deepened responses, and converted more patients to minimal residual disease (MRD)-negative status vs placebo.
Why this matters
- Patients with MM are at high risk for relapse after ASCT.
- Phase 3 TOURMALINE-MM3 randomized study compared maintenance treatment with ixazomib (n=395) vs placebo (n=261) after ASCT in patients with newly diagnosed MM.
- Median patient age: 58 (IQR, 52-64) years.
- Funding: Millennium Pharmaceuticals.
- Median PFS: 26.5 (95% CI, 23.7-33.8) months with ixazomib vs 21.3 (95% CI, 18.0-24.7) months with placebo (HR, 0.72; 95% CI, 0.58-0.89; P=.0023).
- 53% of patients receiving ixazomib converted from partial response (PR) to very good PR or better (≥VGPR) during the study vs 34% with placebo (relative risk [RR], 1.54; 95% CI, 0.94-2.54).
- 46% experienced deepening response during treatment with ixazomib vs 32% with placebo (RR, 1.41; 95% CI, 1.10-1.80; P=.0042).
- 12% of patients converted to MRD negativity at any time during the study with ixazomib vs 7% with placebo.
- Lenalidomide would been a more fitting comparator for ixazomib.